M

Maat Pharma SA
PAR:MAAT

Watchlist Manager
Maat Pharma SA
PAR:MAAT
Watchlist
Price: 7.82 EUR 2.09% Market Closed
Market Cap: 108.6m EUR
Have any thoughts about
Maat Pharma SA?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-3.7
Current
-4.6
Median
4.2
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-3.7
=
Enterprise Value
84.6m EUR
/
EBITDA
-22.7m EUR
All Countries
Close
Market Cap EV/EBITDA
FR
Maat Pharma SA
PAR:MAAT
108.8m EUR -3.7
FR
Pharnext SCA
OTC:PNEXF
6T USD -218 147.8
US
Abbvie Inc
NYSE:ABBV
320.1B USD 15.6
US
Amgen Inc
NASDAQ:AMGN
150.5B USD 16.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.4B USD 25
US
Gilead Sciences Inc
NASDAQ:GILD
113.8B USD 10
US
Epizyme Inc
F:EPE
94.1B EUR -517.9
AU
CSL Ltd
ASX:CSL
135.4B AUD 20.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.9B USD 16.3
US
Seagen Inc
F:SGT
39.3B EUR -59.2
NL
argenx SE
XBRU:ARGX
34.5B EUR -105.2
EBITDA Growth
FR
M
Maat Pharma SA
PAR:MAAT
Average EV/EBITDA: 17.4
Negative Multiple: -3.7
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 147.8 N/A
US
Abbvie Inc
NYSE:ABBV
15.6
29%
US
Amgen Inc
NASDAQ:AMGN
16.8
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25
43%
US
Gilead Sciences Inc
NASDAQ:GILD
10
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -517.9 N/A
AU
CSL Ltd
ASX:CSL
20.5
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.3
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.2 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-3.4
2-Years Forward
EV/EBITDA
-3.1
3-Years Forward
EV/EBITDA
-30.3

See Also

Discover More